<DOC>
	<DOCNO>NCT02215863</DOCNO>
	<brief_summary>Recent review highlight unpredictability complexity immune interference multivalent conjugate vaccine co-administered pediatric vaccine . It become evident likelihood immune interference ( response conjugated- co-administered antigen ) increase proportional number glyco-conjugates ( valency ) dosages carrier protein . There many kind carrier protein : tetanus toxoid ( TT ) , diphtheria toxoid ( DT ) , CRM197 ( non-toxic variant DT ) , OMP ( complex outer-membrane protein mixture Neisseria meningitidis ) non-typeable Hemophilus influenza-derived protein D. Among , TT potent inducer T-helper immunity , carrier-induced-epitopic suppression ( dose-dependent carrier antibody carrier B cell dominance ) may occur TT . In comparison , DT CRM197 weak B-cell immunogen , apparently trigger T-regulatory mechanism . Recent pediatric study PCV13 co-administered DTaP vaccine show 6B GMT ( geometric mean titer ) somewhat reduce compare result PCV13 alone . Similar child , adult frequently visit outpatient clinic get two kind vaccines time : pneumococcal vaccine , influenza vaccine , Td ( diphtheria tetanus ) vaccine , HPV ( human papilloma virus ) vaccine , meningococcal vaccine , zoster vaccine , etc . PCV13 limit co-administration information adjuvanted influenza vaccine . This study design evaluate immunogenicity safety PCV13 MF59-adjuvanted influenza vaccine ( Fluad ) concomitant administration adult age 60 year old .</brief_summary>
	<brief_title>Immunogenicity Safety PCV13 Fluad Adults Aged ≥60 Years</brief_title>
	<detailed_description>This study multi-centered , randomize control clinical trial : Korea University Guro Hospital , Korea University Ansan Hospital , Hallym University Gangnam Sacred Hospital Catholic University Medical College , St. Vincent 's Hospital . The primary objective evaluate immunogenicity Fluad concomitant administration Fluad PCV13 adult age 60 year . This study design demonstrate non-inferiority sero-conversion rate Fluad vaccination : Fluad-PCV13 co-administration group versus Fluad alone group The secondary objective evaluate immunogenicity PCV13 concomitant administration adult age 60 year . This study design demonstrate non-inferiority PCV13 co-administered Fluad compare PCV13 alone . This study also design evaluate safety concomitant PCV13-Fluad administration adult age 60 year . All participant follow duration expect average 4 week vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Adults age ≥60 year sign informed consent Previous pneumococcal vaccine recipient Egg allergy History serious adverse event vaccination , acute disease infection History neurological symptom sign Impairment immune function immunosuppressant use Bleeding diathesis Fever ( define axillary temperature ³38.0°C ) within 3 day ( prior Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Immunogenicity , Safety , MF59 , Influenza vaccine , Pneumococcal vaccine</keyword>
</DOC>